Revolution Medicines (RVMD) Draws M&A Scrutiny on Daraxonrasib FDA Acceptance
Daraxonrasib's Phase 3 survival print has put Revolution Medicines (NASDAQ: RVMD) in focus for potential acquirers. The drug posted 13.2 months median overall survival against 6.7 months for chemotherapy in second-line…
Key takeaways
- Revolution Medicines' daraxonrasib posted 13.2 months median overall survival versus 6.7 months for chemotherapy in second-line pancreatic cancer (HR 0.40; p<0.0001).
- The FDA accepted daraxonrasib's NDA and granted Priority Voucher review, making the FDA decision the next definitive event.
- RVMD shares closed at $205.55 on August 11, 2026, up 492.4% over one year, giving the company a $44.1 billion market cap.
- No M&A deal talks have been confirmed, though Merck and Bristol Myers Squibb are viewed as leading potential acquirers.
- Revolution has no product revenue, a trailing 12-month EPS of negative $8.87, and $3.94 billion in liquidity.
Daraxonrasib's Phase 3 survival print has put Revolution Medicines (NASDAQ: RVMD) in focus for potential acquirers. The drug posted 13.2 months median overall survival against 6.7 months for chemotherapy in second-line pancreatic cancer (HR 0.40; p<0.0001), the FDA accepted the NDA and granted Priority Voucher review, and shares closed at $205.55 on August 11, 2026. The next definitive event is the FDA decision on daraxonrasib.
The numbers
The stock is up 492.4% over one year, giving Revolution a market cap of $44.1 billion. The company carries $3.94 billion in liquidity (cash and marketable securities), including $2.23 billion from spring 2026 capital raises and up to an additional $1.5 billion available under Royalty Pharma arrangements. Management guided FY2026 GAAP operating expenses to $2.10 billion to $2.20 billion. There is no product revenue. Trailing 12-month EPS is negative $8.87.
The pipeline adds to the scarcity case. Elironrasib posted 85% ORR in first-line G12C NSCLC; zoldonrasib showed 82% ORR in G12D NSCLC. RMC-5127 rounds out the late-stage bench. RAS mutations drive roughly 30% of cancers, and Revolution holds the deepest late-stage RAS(ON) pipeline in biotech.
The acquirer list
Merck (NYSE: MRK) sits at the top. Keytruda reported $8.03 billion in Q1 revenue but faces a patent cliff, and CEO Robert Davis has pledged to "transform our portfolio to one with a diversified set of growth drivers." Merck deployed $9.0 billion on Cidara and pursued Verona, Terns, and Halda. Motive and means are aligned.
Bristol Myers Squibb (NYSE: BMY) owns Krazati (KRAS G12C) and already runs a clinical collaboration on daraxonrasib plus navlimetostat. The strategic fit is tightest among named bidders. Net debt near $33.6 billion is the constraint.
Johnson & Johnson (NYSE: JNJ) has a $626.1 billion market cap, AAA credit, and a stated $50 billion oncology target by 2030. It already bought Firefly Bio for KRAS degraders. Price discipline is the offset.
Roche's Genentech operation and Swiss balance sheet make it a live candidate for RAS assets, despite the stock trading outside the United States.
Pfizer (NYSE: PFE) CEO Albert Bourla said he is "particularly encouraged by what we're seeing in oncology," but with $25.38 billion in EBITDA against a stretched post-Seagen balance sheet, a check above $50 billion is a reach.
A leveraged buyout is impractical at $44 billion pre-revenue. Realistic paths run through additional royalty tranches under the Royalty Pharma facility, a large PIPE from crossover funds, or regional partnerships modeled on the recent BeOne Medicines collaboration. Each ranks below a strategic pharma bid.
What to watch
No deal talks have been confirmed. The mean analyst price target stands at $214.71. Insiders were net sellers of roughly $48.6 million over the past 90 days. CEO Mark Goldsmith has called this "a transformational period" tied to "unprecedented Phase 3 results."
Watch for the FDA decision on daraxonrasib, then RASolve 307 and colorectal readouts. Any 13D/13G filing changes the story.
Related reading
Filed via finance.yahoo.com